Cryoservice manager runs the extra mile for Cancer Research
David Bryant completes 145-mile Grand Union Canal Run from Birmingham to London
David Bryant, Cryoservice's business manager for science and industry, took 39 hours 15 minutes to complete the distance, running without sleep or a reasonable break.
‘The race is extremely challenging with only 40% of the starting line up normally finishing, so a hard training regime was required even to be in with a chance of reaching London,’ he said.
‘What kept me going was the knowledge that so many people had sponsored me and that the money raised would be going to a good cause.’
Bryant raised £3,350 for Cancer Research and came 16th.
Cryoservice, a supplier of specialist gases for science, leisure and industry, based in Worcester, UK, is a long-term business partner of Cancer Research UK and was recently short-listed for Supplier of the Year award, in recognition of its commitment and support of the organisation.
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Drug Delivery
Stevanato Group launches Deora pen injector platform targeting GLP-1 and incretin therapies
The fixed-dose, multi-use pull-push device accommodates volumes up to 0.75 mL, offering pharma partners a scalable, error-reducing delivery solution for diabetes and weight management programmes
Finance
GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors
GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.